...
首页> 外文期刊>Advanced drug delivery reviews >Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients
【24h】

Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients

机译:囊性纤维化患者的抗菌素耐药性,呼吸道感染和生物膜在肺部感染中的作用

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Lung infection is the main cause of morbidity and mortality in patients with cystic fibrosis and is mainly dominated by Pseudomonas aeruginosa. The biofilm mode of growth makes eradication of the infection impossible, and it causes a chronic inflammation in the airways. The general mechanisms of biofilm formation and antimicrobial tolerance and resistance are reviewed. Potential anti-biofilm therapeutic targets such as weakening of biofilms by quorum-sensing inhibitors or antibiotic killing guided by pharmacokinetics and pharmacodynamics of antibiotics are presented. The vicious circle of adaptive evolution of the persisting bacteria imposes important therapeutic challenges and requires development of new drug delivery systems able to reach the different niches occupied by the bacteria in the lung of cystic fibrosis patients. (C) 2014 Elsevier B.V. All rights reserved.
机译:肺部感染是囊性纤维化患者发病和死亡的主要原因,并且主要由铜绿假单胞菌(Pseudomonas aeruginosa)控制。生物膜的生长方式使根除感染成为不可能,并导致气道慢性炎症。综述了生物膜形成,抗菌素耐受性和耐药性的一般机制。提出了潜在的抗生物膜治疗目标,例如通过群体感应抑制剂减弱生物膜或在抗生素的药代动力学和药效学指导下杀死抗生素。持久性细菌适应性进化的恶性循环提出了重要的治疗挑战,并需要开发能够到达囊性纤维化患者肺部细菌所占据的不同生态位的新药物递送系统。 (C)2014 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号